FDA News Briefs for Friday, June 28, 2019

These Food and Drug Administration (FDA) developments came in this week:FDA Denies Approval of CeliprololCeliprolol (Acer Therapeutics) is an investigational beta-blocker proposed for the prevention of major complications in patients with vascular Ehlers-Danlos...

FDA Expands Approval of Dupixent

On June 26, 2019, the Food and Drug Administration (FDA) approved a supplemental biologics license application (BLA) for Dupixent (dupilumab; Sanofi and Regeneron Pharmaceuticals Inc.) as an add-on maintenance treatment in adult patients with inadequately controlled...